ArticleEuropean radiology2011
MR Imaging of activated hepatic stellate cells in liver injured by CCl4 of rats with integrin-targeted ultrasmall superparamagnetic iron oxide.
Article in European radiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Inflammatory and resolution stages of hepatic injury: imaging with USPIO-enhanced MRI in mice.European radiology experimental · 2026Article
- Molecular Imaging Probes for Early Detection and Staging of Liver Fibrosis.Chemical & biomedical imaging · 2025Review
- Article
- Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging.Molecular imaging and biology · 2025Review
- A FAPα-activated MRI nanoprobe for precise grading diagnosis of clinical liver fibrosis.Nature communications · 2024Article
- Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis.Biomaterials research · 2024Review
- Enhanced US/CT/MR imaging of integrin αFrontiers in chemistry · 2022Article
- Emerging MRI techniques for molecular and functional phenotyping of the diseased heart.Frontiers in cardiovascular medicine · 2022Review
- Size, shape, charge and "stealthy" surface: Carrier properties affect the drug circulation timeAsian journal of pharmaceutical sciences · 2021Review
- Advances in functional and molecular MRI technologies in chronic liver diseases.Journal of hepatology · 2020Review
- Quantitative evaluation of hepatic integrin αEJNMMI research · 2020Article
- Molecular Probes for Imaging Fibrosis and Fibrogenesis.Chemistry (Weinheim an der Bergstrasse, Germany) · 2019Review
- [Study on diagnostic value of extracellular volume imaging by magnetic resonance imaging for liver fibrosis of hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Molecular magnetic resonance imaging of activated hepatic stellate cells with ultrasmall superparamagnetic iron oxide targeting integrin αvβ₃ for staging liver fibrosis in rat model.International journal of nanomedicine · 2016Article
- Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging.EJNMMI research · 2015Article
- Recent advances in molecular magnetic resonance imaging of liver fibrosis.BioMed research international · 2015Review
- Surface engineered antifouling optomagnetic SPIONs for bimodal targeted imaging of pancreatic cancer cells.International journal of nanomedicine · 2014Article
- Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2013Review
- Molecular MRI of liver fibrosis by a peptide-targeted contrast agent in an experimental mouse model.Investigative radiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo demonstrate the feasibility of the ultrasmall superparamagnetic iron oxide (USPIO) modified by cyclo (Arg-Gly-Asp-Try-Cys) peptide (c(RGDyC)-USPIO) for targeting hepatic stellate cells (HSCs). MATERIALS AND
methodsA c(RGDyC)-USPIO probe was prepared by conjugating c(RGDyC) with USPIO through a thiol-maleinide interaction. The specificity of c(RGDyC)-USPIO for HSCs was investigated in vitro. In vivo, normal and fibrosis rats were treated with either c(RGDyC)-USPIO or USPIO, and magnetic resonance imaging (MRI) of the rats performed after administration of the probes for 4 h. The T2 relaxation times changes before and after probe injection were analyzed and the locations of probes in normal or injured mice were identified histologically.
resultsThe hydrodynamic size of c(RGDyC)-USPIO was 13 ± 3 nm. HSCs took up more specific probes than plain ones. The reduction of T2 relaxation times in fibrosis rat by c(RGDyC)-USPIO was much greater than that by USPIO (P < 0.05). Prussian blue staining and transmission electron microscopy of the injured rat liver treated with c(RGDyC) demonstrated that c(RGDyC)-USPIO were specifically engulfed by the activated HSCs.
conclusionIn vivo cellular targeted imaging of activated HSCs in liver fibrosis using c(RGDyC)-USPIO targeting α(v)β(3) integrins was feasible using a clinical 1.5-Tesla MR system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.